It wasn't that long ago that pharmaceutical giant Merck
According to a MarketWatch
Not so with Merck, which remains a Motley Fool Income Investor recommendation. It's strange when you think about it, with Merck still 44% off its 52-week high. There would seem to be at least some room for an acquirer to buy this company at a premium to its price yet still at a discount to its intrinsic value. Perhaps the answer lies, then, in shareholder anger at the other news from yesterday: a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves.
That's right, Merck shareholders. The guys who who've helped to drop the price of your shares from $90 to $28 in four short years, when faced with the consequences of their actions, have elected to knit themselves a set of first-class golden parachutes, while asking lower-level employees and shareholders to sit quietly and wait for events back in coach. Should Merck experience a "change in control," about 230 senior-level managers (less than one half of one percent of all Merck employees) will receive the right to resign "for good reason" and take a severance package ranging from one and a half times to three times their annual base salary and "target bonus amount." Plus pension benefits. Plus health benefits. Plus immediate vesting of stock options.
Pretty nice deal for the executives, and it should indeed achieve Merck's stated objective of "avoiding the distraction and loss of key management personnel." But as for inspiring the 63,000-odd parachuteless Merck employees, and for reassuring investors that Merck puts its shareholders' interests first, the plan leaves something to be desired.
For more on how Merck reached its present state, read:
Fool contributor Rich Smith owns no shares in any company mentioned in this article.
More from The Motley Fool
1 Stock I'm Buying More Of in 2018
One airline stock is trading for less than 7 times trailing earnings -- even though the company is likely to achieve double-digit EPS growth in 2018.
Vermont Is Legalizing Marijuana in a Unique Way
No state has ever done this before, and it could pave the way for other states to follow in its footsteps.
This Top Dividend Growth Stock Sees No End in Sight
After growing its already lucrative payout 30% last year, this 4.6% yielder sees at least 20% annual growth for the next five years.